Teva Pharmaceutical Industries Limited (TEVA) Announces FDA Acceptance Of NDA Filing For Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI)
7/14/2014 7:02:23 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older.
Help employers find you! Check out all the jobs and post your resume.
comments powered by